ImClone Systems Incorporated And Bristol-Myers Squibb Company Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.

NEW YORK--(BUSINESS WIRE)--ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the companies received a complete response letter from the U.S. Food and Drug Administration (FDA) for the first-line squamous cell carcinoma of the head and neck (SCCHN) supplemental Biologics License Application (sBLA) for ERBITUX® (cetuximab). The sBLA was accepted for filing and granted a priority review status in October 2008.